These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 32087194

  • 21. BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.
    Ponti G, Manfredini M, Greco S, Pellacani G, Depenni R, Tomasi A, Maccaferri M, Cascinu S.
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [Abstract] [Full Text] [Related]

  • 22. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
    Egberts F, Bergner I, Krüger S, Haag J, Behrens HM, Hauschild A, Röcken C.
    Ann Oncol; 2014 Jan; 25(1):246-50. PubMed ID: 24276025
    [Abstract] [Full Text] [Related]

  • 23. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.
    Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, Fonsatti E, Maio M, Botti G, Caracò C, Mozzillo N, Ascierto PA, Cossu A, Palmieri G.
    J Transl Med; 2013 Aug 29; 11():202. PubMed ID: 23987572
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.
    Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, Saturno G, Springer C, Hayes A, Gore M, Larkin J, Marais R.
    Ann Oncol; 2014 May 29; 25(5):959-67. PubMed ID: 24504448
    [Abstract] [Full Text] [Related]

  • 26. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
    Vallée A, Denis-Musquer M, Herbreteau G, Théoleyre S, Bossard C, Denis MG.
    PLoS One; 2019 May 29; 14(8):e0221123. PubMed ID: 31415669
    [Abstract] [Full Text] [Related]

  • 27. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I, Marks L, Kerick M, Klages S, Berking C, Herbst R, Völker B, Schacht V, Timmermann B, Gutzmer R.
    Oncotarget; 2015 Nov 10; 6(35):37895-905. PubMed ID: 26498143
    [Abstract] [Full Text] [Related]

  • 28. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
    Raaijmakers MI, Widmer DS, Narechania A, Eichhoff O, Freiberger SN, Wenzina J, Cheng PF, Mihic-Probst D, Desalle R, Dummer R, Levesque MP.
    Oncotarget; 2016 Nov 22; 7(47):77163-77174. PubMed ID: 27791198
    [Abstract] [Full Text] [Related]

  • 29. MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases.
    Bai X, Kong Y, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J, Si L.
    Clin Cancer Res; 2017 Oct 15; 23(20):6120-6127. PubMed ID: 28720667
    [Abstract] [Full Text] [Related]

  • 30. Germline MC1R variants and frequency of somatic BRAF, NRAS, and TERT mutations in melanoma: Literature review and meta-analysis.
    Zanna I, Caini S, Raimondi S, Saieva C, Masala G, Massi D, Cocorocchio E, Queirolo P, Stanganelli I, Gandini S.
    Mol Carcinog; 2021 Mar 15; 60(3):167-171. PubMed ID: 33444485
    [Abstract] [Full Text] [Related]

  • 31. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.
    Jansen P, Galetzka W, Lodde GC, Standl F, Zaremba A, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Placke JM, Landsberg J, Möller I, Sucker A, Paschen A, Hadaschik E, Zimmer L, Livingstone E, Schadendorf D, Ugurel S, Stang A, Griewank KG.
    Eur J Cancer; 2024 Sep 15; 208():114208. PubMed ID: 39018633
    [Abstract] [Full Text] [Related]

  • 32. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
    Evrenos MK, Temiz P, Çam FS, Yaman M, Yoleri L, Ermertcan AT.
    Turk J Med Sci; 2018 Oct 31; 48(5):973-979. PubMed ID: 30384563
    [Abstract] [Full Text] [Related]

  • 33. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
    Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.
    Eur J Cancer; 2015 Dec 31; 51(18):2792-9. PubMed ID: 26608120
    [Abstract] [Full Text] [Related]

  • 34. The genomic landscape of childhood and adolescent melanoma.
    Lu C, Zhang J, Nagahawatte P, Easton J, Lee S, Liu Z, Ding L, Wyczalkowski MA, Valentine M, Navid F, Mulder H, Tatevossian RG, Dalton J, Davenport J, Yin Z, Edmonson M, Rusch M, Wu G, Li Y, Parker M, Hedlund E, Shurtleff S, Raimondi S, Bhavin V, Donald Y, Mardis ER, Wilson RK, Evans WE, Ellison DW, Pounds S, Dyer M, Downing JR, Pappo A, Bahrami A.
    J Invest Dermatol; 2015 Mar 31; 135(3):816-823. PubMed ID: 25268584
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
    Kodali N, Bhattaru A, Blanchard I, Sharma Y, Lipner SR.
    Melanoma Res; 2024 Oct 01; 34(5):419-428. PubMed ID: 38564430
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.